Homepage > Company > Media > Pharma News > 2016 > AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine.

The British group said on Thursday up it would receive up to $230 million in sales and other related milestones over the lifetime of the contract, with Gruenenthal also paying royalties on sales.

In April, Ironwood Pharmaceuticals bought U.S. marketing rights to the newly approved drug for up to $265 million.

AstraZeneca has a strategy of selling certain rights to non-core medicines as it invests in new drugs. But the disposal of Zurampic has led some analysts to question the success of its past acquisitions, since AstraZeneca only bought the drug's original developer Ardea Biosciences in 2012 for $1.26 billion.

Thu Jun 2, 2016

Source: http://www.reuters.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...